He is a physician-scientist with clinical and research expertise focused on developing novel therapies for children with acute lymphoblastic leukemia (ALL) and rare autoimmune diseases, including autoimmune lymphoproliferative syndrome (ALPS). Dr. Teachey studies new therapies in preclinical models in his research laboratory and then translates these therapies into clinical trials. Dr. Teachey is the Vice Chair for ALL Biology for the Children’s Oncology Group (COG) and is currently the study chair for an international phase 3 clinical trial for children with T-cell ALL. Dr. Teachey is also a specialist in hematopoietic stem cell transplant and in the use of cellular and immunotherapies for the treatment of ALL.